Filtered By:
Condition: Hypertension
Management: Insurance
Countries: USA Health

This page shows you your search results in order of date.

Order by Relevance | Date

Total 19 results found since Jan 2013.

Sleep Duration Is Associated With Subclinical Carotid Plaque Burden
CONCLUSIONS: The association between long sleep and subclinical carotid atherosclerosis may explain prior associations between long sleep and stroke.PMID:37470161 | DOI:10.1161/STROKEAHA.122.041967
Source: Atherosclerosis - July 20, 2023 Category: Cardiology Authors: Christian Agudelo Alberto R Ramos Hannah Gardener Ken Cheung Mitchell S V Elkind Ralph L Sacco Tatjana Rundek Source Type: research

Incidence of cardiometabolic outcomes among people living with HIV-1 initiated on integrase strand transfer inhibitor versus non-integrase strand transfer inhibitor antiretroviral therapies: a retrospective analysis of insurance claims in the United States
CONCLUSIONS: Over a short average follow-up period of <2 years, INSTI use among treatment-naïve PLWH was associated with an increased risk of several cardiometabolic outcomes, such as CHF, myocardial infarction and lipid disorders, compared to non-INSTI use. Further research accounting for additional potential confounders and with longer follow-up is warranted to more accurately and precisely quantify the impact of INSTI-containing ART on long-term cardiometabolic outcomes.PMID:37306118 | PMC:PMC10258864 | DOI:10.1002/jia2.26123
Source: Journal of the International AIDS Society - June 12, 2023 Category: Infectious Diseases Authors: Peter F Rebeiro Bruno Emond Carmine Rossi Brahim K Bookhart Aditi Shah Gabrielle Caron-Lapointe Marie-H élène Lafeuille Prina Donga Source Type: research

Pre-stroke Adherence to Hypertension Medications in a Bi-racial United States Stroke Belt
ConclusionIn this study, adherence to HTN medications was significantly lower among black patients and those without health insurance.
Source: High Blood Pressure and Cardiovascular Prevention - May 26, 2023 Category: Cardiology Source Type: research

Understanding the relationship between perceived discrimination and mortality in United States adults
CONCLUSIONS: Adults experiencing lifetime and daily discrimination had significantly increased risk of mortality after adjusting for predisposing, enabling, and need factors. The findings highlight the importance of screening patients during clinical encounters for experiences of discrimination and providing appropriate resources to mitigate the negative impact of discriminatory events on mortality. Future research should work to fully understand the mechanism by which discrimination increases risk of mortality. These future findings should be used to develop targets for interventions designed to decrease mortality among a...
Source: Aging and Mental Health - February 4, 2022 Category: Geriatrics Authors: Joanna O Obaoye Aprill Z Dawson Madhuli Thakkar Joni S Williams Leonard E Egede Source Type: research

New Analyses Suggest Favorable Results for STELARA ® (ustekinumab) When Used as a First-Line Therapy for Bio-Naïve Patients with Moderately to Severely Active Crohn’s Disease and Ulcerative Colitis
SPRING HOUSE, PENNSYLVANIA, October 25, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from two new analyses of STELARA® (ustekinumab) for the treatment of adults with moderately to severely active Crohn’s disease (CD) and ulcerative colitis (UC).1,2 In a modelled analysisa focused on treatment sequencing using data from randomized controlled trials, network meta-analysis and literature, results showed patient time spent in clinical remission or response was highest when STELARA was used as a first-line advanced therapy for bio-naïve patients with moderately to severely acti...
Source: Johnson and Johnson - October 25, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Janssen Announces U.S. FDA Approval of INVEGA HAFYERA ™(6-month paliperidone palmitate), First and Only Twice-Yearly Treatment for Adults with Schizophrenia
TITUSVILLE, N.J., Sept. 1, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the U.S. Food and Drug Administration (FDA) has approved long-acting atypical antipsychotic INVEGA HAFYERA™ (6-month paliperidone palmitate), the first-and-only twice-yearly injectable for the treatment of schizophrenia in adults. Before transitioning to INVEGA HAFYERA™, patients must be adequately treated with INVEGA SUSTENNA® (1-month paliperidone palmitate) for at least four months, or INVEGA TRINZA® (3-month paliperidone palmitate) for at least one 3-month injection cycle.1 The FDA approval of INVEGA ...
Source: Johnson and Johnson - September 1, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Artificial Intelligence Is Here To Calm Your Road Rage
I am behind the wheel of a Nissan Leaf, circling a parking lot, trying not to let the day’s nagging worries and checklists distract me to the point of imperiling pedestrians. Like all drivers, I am unwittingly communicating my stress to this vehicle in countless subtle ways: the strength of my grip on the steering wheel, the slight expansion of my back against the seat as I breathe, the things I mutter to myself as I pilot around cars and distracted pedestrians checking their phones in the parking lot. “Hello, Corinne,” a calm voice says from the audio system. “What’s stressing you out right n...
Source: TIME: Science - August 26, 2020 Category: Science Authors: Corinne Purtill Tags: Uncategorized Source Type: news

Neuroimaging and Neurolaw: Drawing the Future of Aging
Vincenzo Tigano1, Giuseppe Lucio Cascini2, Cristina Sanchez-Castañeda3, Patrice Péran4 and Umberto Sabatini5* 1Department of Juridical, Historical, Economic and Social Sciences, University of Magna Graecia, Catanzaro, Italy 2Department of Experimental and Clinical Medicine, University of Magna Graecia, Catanzaro, Italy 3Department of Clinical Psychology and Psychobiology, University of Barcelona, Barcelona, Spain 4ToNIC, Toulouse NeuroImaging Center, Université de Toulouse, Inserm, UPS, Toulouse, France 5Department of Medical and Surgical Sciences, University of Magna Graecia, Catanzaro, ...
Source: Frontiers in Endocrinology - April 7, 2019 Category: Endocrinology Source Type: research